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Abstract 23 
HIV-1 induces activation of complement through the classical and lectin pathways. 24 
However, the virus incorporates several membrane-bound or soluble regulators of 25 
complement activation (RCA) that inactivate complement. HIV-1 can also use the 26 
complement receptors (CRs) for complement-mediated antibody-dependent 27 
enhancement of infection (C´-ADE). We hypothesize that polymorphisms in RCA or CRs 28 
that reduce the ability of complement inhibition may protect from HIV-1 infection. For 29 
this purpose, 139 SNPs located in 19 RCA and CRs genes have been genotyped in a 30 
population of 201 Spanish HIV-1 exposed seronegative individual (HESN) and 250 HIV-1 31 
infected patients. Two SNPs were associated with infection susceptibility, rs1567190 in 32 
CR2 (OR = 2.27, P= 1x10-4) and rs2842704 in C4BPA (OR2.11, P= 2x10-4). To replicate 33 
this finding, we analyzed a cohort of Italian, sexually HESN individuals. Although not 34 
significant (P=0.25, OR=1.57), similar genotypic proportions were obtained for the CR2 35 
marker rs1567190. The results of the two association analyses were combined through 36 
a random effect meta-analysis, with a significant P value of 2.6x10-5 (OR=2.07). 37 
Furthermore, we found that the protective CR2 genotype is correlated with lower 38 
levels CR2 mRNA as well as differences in the ratio of the long and short CR2 isoforms.  39 
 40 




HIV-1 is able to activate the classical pathway of complement in the absence of 45 
antibodies, such activation depends on direct binding of C1q envelope protein 1 and 46 
the attachment of C3b on the viral membrane. This fact is enhanced in the presence of 47 
specific anti-HIV-1 antibodies 2. In addition, HIV-1 interacts with Mannose Binding 48 
Lectin (MBL) through direct binding to gp120, triggering the activation of the 49 
complement lectin pathway 3. However, the virus appears to be resistant to 50 
complement 4,5. The biological model to explain this fact is based in the active viral 51 
exploitation of the regulators of complement activation (RCA) protein family. The 52 
exploitation of RCA proteins by several families of viruses is a clear example of 53 
adaptive convergence 6. In the case of HIV-1, it has been demonstrated the absorption 54 
of membrane-bound RCA proteins in virions 4,7,8. These proteins enhance virus 55 
resistance to complement-mediated lysis 4,9,10. This incorporation contributes to the 56 
survival of HIV-1 in blood or other tissues as both virions and infected cells are 57 
resistant to neutralizing antibodies 10. Other soluble proteins such as CFH interacts 58 
with viral envelope 11. Depletion of CFH in human serum increased destruction of cells 59 
infected by HIV-1 and free virus in vitro 11,12. Similarly, viruses produced in cells 60 
defective for any of the RCA proteins are extremely sensitive to killing by serum in the 61 
presence or absence of neutralizing antibodies. Interestingly Streptococcus spp. has 62 
developed a similar strategy of resistance to serum by addition of CFH to its surface by 63 
the M protein 13. Both complement genes and the RCA are extremely polymorphic and 64 
in some cases a functional effect of the polymorphisms has been found 14.  65 
Complement-coated virions are concentrated in several tissues; especially the 66 
lymphatic system and can interact with complement receptors (CRs) that bind C3 67 
fragments. Although viral inactivation through opsonisation and lysis have been 68 
observed 15,  CRs expression in T /B lymphocytes or erythrocytes can also boost viral 69 
infectivity in a process known as complement-mediated antibody-dependent 70 
enhancement of infection (C´-ADE) 16, the CRs implicated in C´-ADE include CR1, CR2 71 
and CR3. Both cis and trans C´-ADE have been observed on cell lines as well as on 72 
primary cells and with primary isolates of HIV-117.  73 
In view of the above interactions of HIV-1 with RCA and complement receptors, we 74 
hypothesized that individuals carrying polymorphisms that reduce the functional 75 
capacity of the CRs or RCA proteins or their site of interaction with gp120/gp41 could 76 
display a natural resistance to HIV-1 infection mediated by an increased probability of 77 
virolisis mediated by full complement activation or lower complement-mediated 78 
enhancement of infection. To address this hypothesis we have performed a genetic 79 
association analysis as well as a phenotypic characterization of RCA and complement 80 
receptors in two independent cohorts of HESN and HIV-1 positive individuals.  81 
 82 
Methods 83 
Patients and controls 84 
We recruited 451 white males exposed to HIV‐1 infection by injection drug use (IDU-85 
Spain), both infected (HIV, 250 subjects) and at HIV‐1 exposed seronegative (HESN, 201 86 
subjects), enrolled in prospective cohort studies in Spain, Arnau de Vilanova Hospital 87 
(Lleida),  Valme Hospital (Sevilla) and Reina Sofía Hospital (Córdoba) who had shared 88 
needles for >3 months 18. Concurrent markers of hepatitis C virus (HCV) infection, one 89 
of the most prevalent blood borne virus, was present in 100% of HESN and HIV‐1 90 
positive subjects. The main epidemiological and clinical characteristics of the series 91 
studied here were described previously 18. Additionally, a second population exposed 92 
to HIV‐1 infection by sexual route was analyzed as replication population; both HIV-1 93 
infected (62 subjects) and HESN (80 subjects), enrolled in prospective cohort studies in 94 
Italy (Sexual-Italy). The main characteristics of this population has been previously 95 
described 19.  96 
Ethical aspects 97 
The study was designed and performed according to the Helsinki declaration and was 98 
approved by the Ethics Committee of the three participating hospitals. All patients and 99 
donors provided written informed consent to participate in this study.  100 
Polymorphism selection and genotyping 101 
SNPs from complement regulatory genes (table 1) were selected according to two 102 
criteria, first, genotype data from Hapmap-CEU population were directly downloaded 103 
from the Hapmap database (www.hapmap.org) and the Tag SNPs were indentified 104 
using Haploview's V4.1 software tagger option 105 
(https://www.broad.harvard.edu/haploview/haploview). Second, SNPs list were 106 
completed with potentially functional polymorphisms previously associated or not 107 
with disease. DNA was extracted from fresh peripheral blood mononuclear cells or 108 
frozen whole blood using the Quick Pure Blood DNA extraction Kit (Macherey-Nagel, 109 
Düren, Germany) or Magna Pure system (Roche, Basel, Switzerland). The SNPs were 110 
genotyped using a custom Golden Gate Veracode genotyping assay (Illumina, San 111 
Diego, California USA). Original genotyping data are available upon request. 112 
Sequencing of C4BPA, CD55, CR2 and CR1 chromosome region 113 
DNAs from 33 HESN individuals, homozygous CC for the rs1567190 SNP associated 114 
with the resistant phenotype, were mixed in 3 independent pools. In parallel, DNA 115 
from 46 HIV positive individuals homozygous TT associated with the risk phenotype 116 
were mixed in 5 independent pools. Sequencing of each pool DNA was done by custom 117 
capture and New Generation Sequencing using Illumina HiSeq2000 sequencer in 118 
Otogenetics facilities (www.otogenetics.com). The resequencing strategy was focused 119 
on 515.844 bp from chromosome 1 region including the genes C4BPA, CD55, CR2 and 120 
CR1 (coordinates from 207.224.455 bp to 207.740.299 bp, NCBI buildGRCh37/hg19). 121 
Raw data generated were analyzed using the SNP discovery tool of DNAnexus cloud 122 
computing software (www.dnanexus.com). We calculate a score for each polymorphic 123 
position identified (frequency of reads equal to the consensus sequence/number of 124 
total reads). The original sequencing data are available upon request.  125 
Biostatistics and bioinformatics 126 
Hardy‐Weinberg equilibrium and pairwise linkage disequilibrium (D′) were calculated 127 
using Haploview V4.1 software. Block structure was considered for marker pairs 128 
showing D′ > 0.8, following the solid‐spine block definition implemented in Haploview. 129 
Single marker and haplotype frequencies were estimated and compared using PLINK 130 
software, complemented with the Java-based implementation software gPLINK 131 
(http://pngu.mgh.harvard.edu/ ~purcell/plink/gplink.shtml). Complementary analysis 132 
was performed by use of SPSS software (version 14.0). Single‐marker association P 133 
values were corrected for multiple testing following the SNP spectral decomposition 134 
approach 20, experiment-wide significance threshold required to keep type I error rate 135 
at 5% was 5 10-4. Haplotype association tests were adjusted using a Bonferroni´s 136 
correction for multiple testing by dividing the significance level (0.05) by the number of 137 
major haplotypes (i.e., >5%), a p value < 5 10-3 was considered statistically significant.  138 
CR2 and C4BPA mRNA quantification 139 
PBMC from healthy blood donors (City of Jaen, Blood Bank) were purified by 140 
centrifugation in Ficoll gradient, DNA was extracted as previously described and 141 
genotyped for the SNPs rs1567190 of CR2 and rs2842704 of C4BPA with Taqman 142 
probes. Nine individuals harboring CC genotype and nine with TT genotype for CR2 and 143 
ten individuals carrying AA genotype and ten with AG/GG genotype for C4BPA were 144 
randomly selected gene expression analyses. Then, from each sample, total RNA from 145 
5x106 PBMCs was isolated using Tripure reagent (Roche), quantified by 146 
spectrophotometry and disolved at 1 μg/μl. Reverse transcription of RNA was 147 
performed using the Superscript III (Invitrogen), following manufacturer’s instructions. 148 
All the RNA samples were also subjected to control reactions without reverse 149 
transcriptase to check for contamination. The normalized CR2 expression was 150 
determined in a multiplexed, one tube PCR reaction using the CD19 as endogenous 151 
control (Hs01047410_g1, Applied Biosystems) and CR2 Gene Expression Assays 152 
(Hs00153398_m1 FAM probe, Applied Biosystems). Quantitative real-time PCRs were 153 
performed in a total volume of 12.5 μl containing 6.25 μl of Quantimix Easy probes 154 
master mix (Biotools, Madrid, Spain), 0.25 μl of each probe/primer set CD19 and 1 μl 155 
of probe/primer set for CR2, 2 μl of cDNA and 3 μl of water. Cycling conditions were: 156 
95 °C for 10 min, and 45 cycles at 95 °C for 15 s, 60 °C for 1 min. Similarly C4BPA 157 
expression was quantified. In that case, CD14 probe (Hs001691220_g1 VIC Probe, 158 
Applied Biosystems) was used as endogenous control mixed in the same PCR reaction 159 
tube with C4BPA probe (Hs00426339_m1 HEX probe, Applied Biosystems).  The real-160 
time PCR reaction were prepared in a total volume of 12.5 μl containing 6.25 μl of 161 
Quantimix Easyprobes master mix (Biotools, Madrid, Spain), 0.5 μl of each 162 
probe/primer set for CD14 and 1.2 μl of probe/primer set for C4BPA, 2 μl of cDNA and 163 
2.55 μl of water. Cycling conditions were: 95 °C for 10 min, and 45 cycles at 95 °C for 164 
25 s, 60 °C for 1 min. Fluorescence was monitored at the end of each annealing phase 165 
on a MX3005P thermocycler (Stratagene, La Jolla, CA, USA). Each donor cDNA were 166 
amplified in duplicate wells, and repeated in two independent days. Parallel negative 167 
control experiments were done with reverse transcriptase negative cDNAs. The 168 
relative expression of CR2 and C4BPA mRNAs compared to endogenous CD19 (CR2) or 169 
CD14 (C4BPA) were calculated using the algorithm - CT implemented in the MX-pro 170 
V4.0 software (Stratagene) according to manufacturer’s instructions. The Comparative 171 
quantitation of short and long isoform of CR2 transcripts has been done as previously 172 
described 21 173 
Results 174 
Genotyping statistics 175 
Four SNPs did not passed the genotyping quality controls of Illumina Veracode Golden 176 
Gate protocol rs7084554 (MBL2), rs12406509 (CFHR4), rs7046 (CD59) and rs9837104. 177 
Additionally, we found significative deviation from HWE (P=1.3 10-5) in the marker 178 
rs9331949 (CLUS). Mean genotyping call rates for the rest of the SNPs were 99.6%.  179 
Univariate genetic association analysis 180 
We selected 139 polymorphic markers (Table 1) within regulators of complement 181 
activation and complement receptors genes for susceptibility to HIV-1 association in 182 
the IDU-Spain cohort. Two intronic SNPs positioned in the same region of the 183 
chromosome 1 (Figure 1), showed experiment-wide significant allelic or genotypic 184 
association with resistance to HIV infection. The G allele of rs2842704 in C4BPA was 185 
associated with decreased risk of infection under dominant model (P=2x10-4; OR: 0.47 186 
[0.31-0.70]). Subjects carrying GG+AG genotypes were significantly over-represented 187 
in HESN group (43%) compared to HIV-1 infected one (26%) (Table 2). Regarding CR2 188 
gene, the T allele of rs1567190 was associated with increased risk of HIV infection 189 
under a dominant model (P=1x10-4; OR: 2.27 [1.46-3.51]) (Table 3). Subjects carrying 190 
TT+TC genotypes were significantly over-represented in the HIV+ group (81%) 191 
compared to HESN (65.5%). Three other SNPs showed a trend to association with HIV-192 
1 infection protection but did not reach statistical significance after correction by 193 
multiple testing; rs419137 in CFH (P=6x10-3), rs831618 in CD59 (P=7x10-3) and 194 
rs6690037 in C4BPB (P=8x10-3) (supplementary table 1).  195 
Additionally to replicate the previous findings, rs2842704 in C4BPA and rs1567190 in 196 
CR2 were genotyped in a second population (Sexual-Italy) exposed to the virus through 197 
sexual route. Both genetic markers were in accordance with the HWE law. Genotype 198 
distribution of rs2842704 marker differs to that observed in the IDU-Spain sample not 199 
supporting the observed association for this SNP in the IDU-Spain cohort (Table 3).  200 
Similarly to what was observed in the IDU-Spain sample, CR2 rs1567190 TT+TC 201 
genotype was over-represented in HIV-1 (77.5%) compared to HIV-1 (68.5%), although 202 
it did not reach statistical significance (P=0.25; OR: 1.57 [0.7-3.4]) Table 3). The results 203 
of the two association analyses were combined through a random effect metaanalysis, 204 
with a significant p value of 2.6x10-5 (Table 3). These observations suggest that the T 205 
allele of rs2074560 confers risk to HIV-1 infection with a dominant effect, 206 
independently infection route.  207 
Haplotype association analysis in Spanish intravenous drug users 208 
A haplotype-based association test was performed by multimarker regression analysis 209 
using Plink and Haploview software. Haplotype frequencies were estimated and 210 
compared between the two groups of the IDU-Spain cohort. This analysis identified 3 211 
haplotypes associated with HIV-1 resistance with a significant multiple-testing p value 212 
<5x10-3.  Haplotypes from, CFH, C4BPA and CR2 genes included SNPs previously 213 
identified as associated in the univariate analysis (Table 4). Using Plink software, we 214 
calculated the chromosome phases for HESN and HIV groups and performed haplotype 215 
copy number calculation in HIV-1 positive and HESN individuals. The presence of 2 216 
copies of the haplotype CGGGG encompassing the promoter, and the first 12 exons of 217 
CR2 (rs1567190, rs1507764, rs1048971, rs17615, rs4317805) showed the strongest 218 
association with protection under a recessive model (P=8x10-5) (table 4). The other two 219 
haplotypes associated with innate resistance to HIV-1 infection followed a dominant 220 
model and included presence of one or two copies the haplotype GCT (rs2842704, 221 
rs4425986 and rs9943077) located in the fourth intron of C4BPA (P=1.1x10-3) (Table 4). 222 
As well as the haplotype AAACTGCG (rs2019727, rs6695321, rs10737680, rs419137, 223 
rs395544, rs2284664, rs11582939, rs16840658) that spam from the intron 9 of CFH to 224 
the 5´ end of CFHR1 gene (Table 4).  225 
Sequencing of C4BPA, CD55, CR2 and CR1 chromosome region 226 
In order to identify new functional SNPs in the candidate region and perform a 227 
sequence haplotying, a mean of 900,000 bp have been sequenced confidently with a 228 
30X mean coverage. Spanning the chromosome 1 region 207,224,455-207,740,299 229 
(GRCh37/hg19); including C4BPB, C4BPA, CD55, CR2, CR1 and CR1L in 5 pools of HIV 230 
positive homozygous for the risk (T) allele of the SNP rs1567190 and 3 pools of HESN 231 
patients homozygous for the protective (C) allele of the SNP rs1567190. The main 232 
statistics for pool sequencing can be found in Supplementary Table 2. We observed a 233 
perfect match between the two genotyping systems Veracode Golden Gate and New 234 
Generation Sequencing. A total of 189 new polymorphic sites have been identified in 235 
the region (supplementary table 3), most of them located in introns or intergenic 236 
regions. Only one SNP produces a non-synonymous coding change in the CR1 gene 237 
(supplementary table 3). The individuals homozygous for the C allele of rs1567190 are 238 
also homozygous for 52 polymorphisms spanning 45 Kb of the CR2 gene (Figure 3, 239 
supplementary table 4). In particular these individuals are homozygous for the coding 240 
SNPs rs1048971, rs17615, rs4308977, rs17616 (G-G-T-G). On the contrary, individuals 241 
homozygous for the risk allele of rs1567190 displayed a lower level of homozygosity 242 
along the CR2 gene, only 11 polymorphisms are also homozygous and only one of 243 
them (rs17258982) are located in the CR2 coding region (Figure 3, Supplementary 244 
Table 4).  245 
CR2 and C4BPA phenotyping  246 
Next, we validated whether the observed effect could be associated with differential 247 
expression of CR2 mRNA in PBMC from healthy donors. Nine samples homozygous CC 248 
for rs1567190 of CR2, and nine homozygous TT samples were examined by Taqman 249 
real-time quantitative PCR. The relative amount of the CR2 expression of different 250 
genetics backgrounds were measured normalized to CD19 (a specific B- lymphocyte 251 
marker). The normalized expression of CR2 revealed a lower level of expression of the 252 
protective genotype CC (n=9, mean=0.39±0.08) compared to the risk genotype TT 253 
(n=9, mean=0.77±0.11; P=0.014, Student T-test, Figure 2). These data suggest that the 254 
global level of CR2 expression is increased in B-lymphocytes from rs1567190 TT 255 
carriers. These data represent the mean of two independent experiments performed 256 
in duplicate. The levels of the short and long CR2 mRNA splicing isoforms were also 257 
quantified by real time PCR in both genetic backgrounds. The CD19-normalized short 258 
CR2 isoform expression were significatively reduced in PBMC from homozygous CC 259 
individuals compared with TT (n=9, mean=0.12±0.09 vs. 0.64±0.19; P=0.024, Student T-260 
test, Figure 2). Finally, we have found that the expression of long CR2 isoform in 261 
rs1567190 CC carriers is more elevated (although without reaching statistical 262 
signification) compared to the other genotype (n=9, mean=1.9±1.04 vs. 0.07±0.07; 263 
P=0.09, Student T-test, Figure 2).  264 
The mRNA levels of C4BPA normalized by CD19 in PBMC from individuals harboring the 265 
protective genotype does not display significative differences with the risk genotype 266 
(n=9, mean=0.36±0.81 vs. 0.26±0.26; P=0.77, Student T-test).  267 
 268 
  269 
Discussion  270 
In this hypothesis-driven, low-scale, candidate gene association study we have 271 
genotyped 139 SNPs in 19 genes related to complement regulatory proteins or 272 
complement receptors. Our discovery population is highly uniform: all are male, white 273 
Caucasians of Spanish ancestry, HCV positive and intravenous drug users; including 201 274 
HESN and 250 HIV-1 positive. We found two SNPs that are significantly associated after 275 
Bonferroni´s correction with resistance to HIV-1 infection; rs1567190 located in CR2 276 
and rs2842704 in C4BPA. A metanalysis including an independent cohort of HESN 277 
individuals from Italy at risk of infection through sexual route gave support only the 278 
association of CR2 with the risk of infection.  279 
This study has several limitations, first, the list of genes related to complement system 280 
is not exhaustive; polymorphisms in other genes not included in this study may also be 281 
considered as potential modulators of HIV-1 susceptibility, additionally some genes 282 
included in this study, as CFHR1 or CD55 are represented by only one to three SNPs. 283 
Second, our phenotypic analysis is limited to mRNA expression; inclusion of protein 284 
quantification as well as complement-mediated antibody-dependent enhancement of 285 
infection in the context of CR2 isoforms and C4BP overexpression may give us a more 286 
complete picture of the role these polymorphisms in HIV-1 susceptibility and it will 287 
generate new tools to counteract the viral subversion of the complement system. 288 
Third, the sizes of our HESN cohorts are very limited and do not allow us to perform 289 
epistatic or gene-gene interaction analysis. Four, the replication cohort from Italy is 290 
significatively smaller than the Spanish one and the genetic factors affecting the innate 291 
resistance against HIV-1 infection through sexual route could be different compared to 292 
the parenteral one.  293 
The CR2 gene encodes a membrane protein also known as CD21, which functions as a 294 
receptor for five ligands: C3d/iC3b, Epstein-Barr Virus, CD23 22, Interferon alpha 23 and 295 
DNA 24. CR2 together with CD19, CD81, and CD225, forms the B-cell coreceptor 296 
complex in the surface of B lymphocytes, and binding of CR2 with immune complexes 297 
coated with C3 results in B-lymphocyte enhanced proliferation, up regulation of co-298 
stimulatory molecules, and activation of intracellular signaling pathways including 299 
calcium release or MAP kinase activation (Cambier et al., 1994; Matsumoto et al., 300 
1991). On Follicular dendritic cells (FDCs) CR2 captures C3 coated antigens, apparently 301 
to hold these on the surface for long periods of time, facilitating a prolonged immune 302 
response 25.  CR2 gene contains 18 exons and there exist two main isoforms that 303 
results from alternative splicing of exon 11: CR2-L and CR2-S. The first form is 304 
expressed mainly in follicular dendritic cells and contains 16 short consensus repeats 305 
(SCRs); the second isoform is expressed principally in B lymphocytes, some T activated 306 
cells and endothelial cells and it contains 15 SCRs. Both SCRs form the extracellular 307 
domain 21.  The specific functions of each isoform as well as its binding capacity to the 308 
natural ligands are unknown.  309 
CR2 function can be subverted by some viruses that use antibodies and/or 310 
complement for a highly efficient entry into target cells; in a process known as 311 
antibody-dependent enhancement (ADE) of viral infection. Two types of ADE have 312 
been described in the context of HIV-1. The first type of ADE is dependent on the 313 
interaction between antibody and FcR, specifically the FcRIIIa appears to be the most 314 
important receptor for FcR-dependent ADE, and polymorphisms in this gene were 315 
associated with outcomes in a trial testing recombinant gp120 vaccination in 316 
preventing sexually acquired HIV-1 infection 26. Second, complement alone can boost 317 
infection of dendritic cells as well as monocytes/macrophages and antibodies can 318 
augment this process by a more efficient recruitment of complement on the viral 319 
surface. This mechanism is dependent on the CR2/CR1 expression in the target cells 320 
17,27 and probably is mediated by and increased adhesion of the virus-antibody-321 
complement (C3d) complexes through binding with CR2 on the target surface 28 29. The 322 
protective SNP identified in this study, belongs to an extended haplotype that display 323 
strong linkage disequilibrium and include other 52 genetic polymorphisms that spam 324 
45 Kb from the promoter to 3´ downstream region. The protective CR2 haplotype 325 
displays lower levels of total CR2 mRNA as well as reduced short isoform expression; in 326 
view of the data about the role of CR2 in complement-mediated ADE, we hypothesize 327 
that the ratio of short/long CR2 isoform expression and/or the global CR2 level, may 328 
contribute to the likelihood of HIV-1 acquisition through the parenteral as well as 329 
sexual routes. ADE is an important factor affecting other viruses as Dengue, Ross River 330 
or Ebola 16; we conjecture that the CR2 haplotypes could have also an influence in the 331 
susceptibility to these viruses. Although the main SNP identified in this study has not 332 
been previously related with any pathology, the protective haplotype has been 333 
associated with susceptibility to systemic lupus erythematosus 30 21.   334 
C4BPA gene encodes a plasma protein that forms an oligomer complex with C4BPB, 335 
producing three isoforms: α7β1, α7β0 y α6β1. C4BP is a plasmid regulator of the 336 
classical and alternative complement pathways. It hydrolyzes the complement 337 
fragment C4b, accelerates the degradation of the C3 convertase and regulates as a 338 
cofactor the alternative pathway by binding to Factor I 31. Gene expression profiling of 339 
peripheral blood mononuclear cells from patients with acute HIV-1 infection has 340 
identify C4BPA as a protein capable of restrict HIV-1 replication 32. Other viruses as 341 
Dengue, West Nile or yellow fever actively recruit C4BP through the NS1 protein, 342 
reducing the functional capacity of C4 and complement activation. Bacterial infections 343 
as Streptococcus 33 , Yersinia 34, Lepstospira 35 or Neisseria 36 among others, have also 344 
developed active protein systems to capture C4BP in the surface to escape 345 
complement mediated lysis. The observed association of C4PBA haplotypes with HIV-1 346 
resistance in HESN at risk thought the parenteral route suggests that this gene could 347 
be a candidate for further functional phenotypic characterization. Several observations 348 
may underlie the absence of association of C4BPA marker in the Italian cohort at risk 349 
through the sexual route. First, this cohort is mainly constituted by women 19 and the 350 
Spanish one is exclusively constituted by males. There are significative gender 351 
differences in the innate and adaptive immune responses, the pathogenesis of 352 
infectious diseases, response to vaccines and the prevalence of autoimmune diseases 353 
37,38. In the case of C4BP, the synthesis appears to be influenced by sex hormones 39, 354 
pregnancy 40 or contraceptive treatment 41.  Finally, environmental factors as HCV 355 
infection (with 100% prevalence in the Spanish cohort) may modulate the genetic 356 
susceptibility in the drug users but not in the sexual cohort. HCV actively interferes 357 
with the complement system, inhibiting the transcription and protein production of C3 358 
42, C4 43 and C9 44.  359 
CFH regulates the function of the alternative complement pathway in fluid phase and 360 
on cellular surfaces. It binds to C3b, accelerates the decay of the alternative pathway 361 
convertase C3bBb, and also acts as a cofactor for complement factor I, another C3b 362 
inhibitor 45 46. The CFH gene consists of 20 short consensus repeats (SCR), each of 363 
which encodes a functional domain containing a C3d/C3b binding site 47 14. CFH is 364 
synthesized primarily by the liver and secreted into the circulation 14. SNPs in the   CFH 365 
region that appears to be related with HIV-1 resistance at the haplotypic level, has 366 
been previously associated with several autoimmune diseases 14; as well as 367 
susceptibility to meningitis 48 and Dengue 49. High levels of CFH in human serum can 368 
protect cells infected by HIV-1 and free virus in vitro  [14,22,23,24], we hypothesize 369 
that the protective haplotype of CFH may be related to lower levels of CFH expression 370 
by the liver or altered splicing efficacy.  371 
The discovery of genetic polymorphisms associated with innate resistance to HIV-1 372 
infection can increase our understanding on the viral replication and spreading 373 
strategies and can potentially lead to the identification of new antiviral targets acting 374 
on the host proteins needed by the virus to achieve optimal replication or immune 375 
escape. The results presented here if confirmed, could lead to develop alternative 376 
strategies to combat the viral infection by the means of development of new 377 
antagonists of CR2, C4BPA or CFH. This approach has formerly assayed using inhibitors 378 
of CD59 50, another membrane-bound RCA implicated in HIV-1 resistance to serum. 379 
Finally, our results may have implications in the pharmacogenetics of HIV-1 vaccine.  380 
   381 
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  527 
Figures legends 528 
 529 
Figure 1: Scatter plot of genetic association results. Negative log10-transformed P-530 
values are plotted against physical position in the chromosome 1. SNPs rs2842704 531 
rs1567190 are statistically significant after Bonferroni´s correction.  532 
 533 
Figure 2: CR2 mRNA expression normalized by CD19 according to the genotype for 534 
rs1567190. a) Global CR2 expression levels (P=0.014) b) Short CR2 isoform (P=0.024) 535 
and c) Long CR2 isoform (P=0.77).  536 
 537 
Figure 3: Sequence-inferred haplotypes of CR2 gene in pools of HESN with protective 538 
(a) or HIV-1 infected patients with risk (b) genotypes. The Y-axis represents the % of 539 
reads with consensus sequence. The X-axis represents the relative position of CR2 540 
SNPs along the gene. 541 
 542 
 543 
